Would you continue adjuvant FOLFOX for a patient with stage III colon cancer and triple-vessel coronary artery disease who developed NSTEMI after the first cycle?

This is a challenging scenario where the patient has existing triple vessel CAD and developed NSTEMI after 1st cycle. We all agree that 5-FU based therapy is the backbone for adjuvant therapy of stage III colon cancers. There are no clear cut guidelines in this case and management is per expert recommendations based on retrospective data. I would have the following comments on this case:

1. It is extremely important to include cardio-oncology in the management of this patient. Cardio-oncology input can be valuable in delineating whether this is 5-FU induced cardio-toxicity vs related to pre-existing CAD. The etiology of cardio-toxicity is essential: is it related to coronary vasospasm vs infarct/thromboembolic.

2. Is this a low risk vs high ...